Topoisomerase II-mediated DNA cleavage and mutagenesis activated by nitric oxide underlie the inflammation-associated tumorigenesis

Antioxidants and Redox Signaling

Volumn 18, Issue 10, 2013, Pages 1129-1140

  Yang, Yu Chen ^a   Chou, Han Yi E ^b   Shen, Tang Long ^b   Chang, Wei Jer ^a   Tai, Pei Han ^b   Li, Tsai Kun ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; HISTONE H2AX; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROTEIN P53; S NITROSOGLUTATHIONE;

ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA SEQUENCE; DNA STRAND BREAKAGE; ENZYME PHOSPHORYLATION; INFLAMMATION; MACROPHAGE; MELANOMA; MOUSE; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; COCULTURE TECHNIQUES; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; HCT116 CELLS; HL-60 CELLS; HUMANS; INFLAMMATION; MICE; MICE, KNOCKOUT; MUTAGENESIS; NITRIC OXIDE; NITRIC OXIDE DONORS; PYRIDINES; S-NITROSOGLUTATHIONE;

EID: 84874059703     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4620     Document Type: Article

References (43)

1. Andoh T. Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs. Biochimie 80: 235-246, 1998.
2. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, and Liu LF. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci USA 104: 11014-11019, 2007.
3. Bartek J, Hamerlik P, and Lukas J. On the origin of prostate fusion oncogenes. Nat Genet 42: 647-648, 2010.
4. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, and Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870, 2005.
5. Calmels S, Hainaut P, and Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res 57: 3365-3369, 1997.
6. Castiglione N, Rinaldo S, Giardina G, Stelitano V, and Cutruzzola F. Nitrite and nitrite reductases: From molecular mechanisms to significance in human health and disease. Antioxid Redox Signal 17: 684-716, 2012.
7. Chazotte-Aubert L, Hainaut P, and Ohshima H. Nitric oxide nitrates tyrosine residues of tumor-suppressor p53 protein in MCF-7 cells. Biochem Biophys Res Commun 267: 609-613, 2000.
8. Chazotte-Aubert L, Oikawa S, Gilibert I, Bianchini F, Kawanishi S, and Ohshima H. Cytotoxicity and site-specific DNA damage induced by nitroxyl anion (NO(-)) in the presence of hydrogen peroxide. Implications for various pathophysiological conditions. J Biol Chem 274: 20909-20915, 1999.
9. Classen S, Olland S, and Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci USA 100: 10629-10634, 2003.
10. Colotta F, Allavena P, Sica A, Garlanda C, and Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 30: 1073-1081, 2009.
11. D'Antuono M, Biagini G, Tancredi V, and Avoli M. Electrophysiology of regular firing cells in the rat perirhinal cortex. Hippocampus 11: 662-672, 2001.
12. Daroui P, Desai SD, Li TK, Liu AA, and Liu LF. Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death. J Biol Chem 279: 14587-14594, 2004.
13. Fan JR, Peng AL, Chen HC, Lo SC, Huang TH, and Li TK. Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses. DNA Repair (Amst) 7: 452-463, 2008.
14. Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, and Xie XJ. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: Correlation with clinical features. BMC Cancer 2: 8, 2002.
15. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Jr., Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, and Halazonetis TD. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913, 2005.
16. Gupta SC, Hevia D, Patchva S, Park B, Koh W, and Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: The roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 16: 1295-1322, 2012.
17. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, and Yegnasubramanian S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 42: 668-675, 2010.
18. Hanahan D and Weinberg RA. Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
19. Harker WG, Slade DL, Parr RL, and Holguin MH. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res 55: 4962-4971, 1995.
20. Hellmann K. Overview and historical development of dexrazoxane. Semin Oncol 25: 48-54, 1998.
21. Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, and Harris CC. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 100: 143-148, 2003.
22. Huang TH, Chen HC, Chou SM, Yang YC, Fan JR, and Li TK. Cellular processing determinants for the activation of damage signals in response to topoisomerase I-linked DNA breakage. Cell Res 20: 1060-1075, 2010.
23. Li TK, Chen AY, Yu C, Mao Y, Wang H, and Liu LF. Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidative stress. Genes Dev 13: 1553-1560, 1999.
24. Li TK, Houghton PJ, Desai SD, Daroui P, Liu AA, Hars ES, Ruchelman AL, LaVoie EJ, and Liu LF. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res 63: 8400-8407, 2003.
25. Li TK and Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41: 53-77, 2001.
26. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, and Netto GJ. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 24: 820-828, 2011.
27. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, and Liu LF. Topoisomerase IIbeta mediated DNA doublestrand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67: 8839-8846, 2007.
28. Moncada S, Palmer RM, and Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142, 1991.
29. Montecucco A and Biamonti G. Cellular response to etoposide treatment. Cancer Lett 252: 9-18, 2007.
30. Mosser DM and Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969, 2008.
31. Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9: 327-337, 2009.
32. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9: 338-350, 2009.
33. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, and Chinnaiyan AM. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16: 793-798, 2010.
34. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis-Filho JS, Kumar-Sinha C, and Chinnaiyan AM. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 17: 1646-1651, 2011.
35. Rowley JD. The critical role of chromosome translocations in human leukemias. Annu Rev Genet 32: 495-519, 1998.
36. Salk JJ, Salipante SJ, Risques RA, Crispin DA, Li L, Bronner MP, Brentnall TA, Rabinovitch PS, Horwitz MS, and Loeb LA. Clonal expansions in ulcerative colitis identify patients with neoplasia. Proc Natl Acad Sci USA 106: 20871-20876, 2009.
37. Solovyan VT, Bezvenyuk ZA, Salminen A, Austin CA, and Courtney MJ. The role of topoisomerase II in the excision of DNA loop domains during apoptosis. J Biol Chem 277: 21458-21467, 2002.
38. Wang H, Mao Y, Chen AY, Zhou N, LaVoie EJ, and Liu LF. Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 40: 3316-3323, 2001.
39. Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW, and Chan NL. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 333: 459-462, 2011.
40. Xiao H, Li TK, Yang JM, and Liu LF. Acidic pH induces topoisomerase II-mediated DNA damage. Proc Natl Acad Sci USA 100: 5205-5210, 2003.
41. Yamazaki F, Okamoto H, Matsumura Y, Tanaka K, Kunisada T, and Horio T. Development of a new mouse model (xeroderma pigmentosum a-deficient, stem cell factor-transgenic) of ultraviolet B-induced melanoma. J Invest Dermatol 125: 521-525, 2005.
42. Zhang Y, Strissel P, Strick R, Chen J, Nucifora G, Le Beau MM, Larson RA, and Rowley JD. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci USA 99: 3070-3075, 2002.
43. Zhou N, Xiao H, Li TK, Nur EKA, and Liu LF. DNA damage-mediated apoptosis induced by selenium compounds. J Biol Chem 278: 29532-29537, 2003.